The history of Viagra presents a interesting case for investors in the medicinal sector. While initially a phenomenal success, generating billions, the patent expiration and the subsequent entry of off-brand alternatives have drastically impacted revenue. This raises questions about the future sustainability of analogous drug projects and suggests